Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review
Background. It has been found that there is overactivation of immune response in patients with COVID-19. Several studies are going on to assess the role of immunomodulation. IL-6 antibodies such as tocilizumab have been found to have efficacy in the treatment of COVID-19. We aim to assess the role o...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Interdisciplinary Perspectives on Infectious Diseases |
| Online Access: | http://dx.doi.org/10.1155/2021/8903435 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849401530182008832 |
|---|---|
| author | Rajan Chamlagain Sangam Shah Basanta Sharma Paudel Roman Dhital Bipin Kandel |
| author_facet | Rajan Chamlagain Sangam Shah Basanta Sharma Paudel Roman Dhital Bipin Kandel |
| author_sort | Rajan Chamlagain |
| collection | DOAJ |
| description | Background. It has been found that there is overactivation of immune response in patients with COVID-19. Several studies are going on to assess the role of immunomodulation. IL-6 antibodies such as tocilizumab have been found to have efficacy in the treatment of COVID-19. We aim to assess the role of sarilumab in the treatment of COVID-19 through this review. Main Body. Functional outcomes were assessed on the basis of PaO2/FiO2 ratio, mortality, and ventilation. Adverse events of studies were also noted. Five studies were included in the study. There was improvement in PaO2/FiO2 ratio, reduction in the mortality of the patients, and less number of patients were on ventilation, but there were no significant differences among the comparison and sarilumab group. Sarilumab did not have notable adverse events and can be considered a safe drug. Conclusion. Sarilumab is a safe drug with good clinical outcomes in patients with COVID-19 and, hence, could be used as an alternative regimen for the treatment. Further prospective studies exploring the relations with baseline biomarkers of inflammation commonly measured such as C-reactive protein and IL-6 would be necessary for a correlation with the treatment. |
| format | Article |
| id | doaj-art-8cb9567a63b1497680fe52017e1565c8 |
| institution | Kabale University |
| issn | 1687-708X 1687-7098 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Interdisciplinary Perspectives on Infectious Diseases |
| spelling | doaj-art-8cb9567a63b1497680fe52017e1565c82025-08-20T03:37:44ZengWileyInterdisciplinary Perspectives on Infectious Diseases1687-708X1687-70982021-01-01202110.1155/2021/89034358903435Efficacy and Safety of Sarilumab in COVID-19: A Systematic ReviewRajan Chamlagain0Sangam Shah1Basanta Sharma Paudel2Roman Dhital3Bipin Kandel4Tribhuvan University Teaching Hospital, Maharajgunj, Kathmandu 44600, NepalMaharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Maharajgunj, Kathmandu 44600, NepalTribhuvan University Teaching Hospital, Maharajgunj, Kathmandu 44600, NepalTribhuvan University Teaching Hospital, Maharajgunj, Kathmandu 44600, NepalTribhuvan University Teaching Hospital, Maharajgunj, Kathmandu 44600, NepalBackground. It has been found that there is overactivation of immune response in patients with COVID-19. Several studies are going on to assess the role of immunomodulation. IL-6 antibodies such as tocilizumab have been found to have efficacy in the treatment of COVID-19. We aim to assess the role of sarilumab in the treatment of COVID-19 through this review. Main Body. Functional outcomes were assessed on the basis of PaO2/FiO2 ratio, mortality, and ventilation. Adverse events of studies were also noted. Five studies were included in the study. There was improvement in PaO2/FiO2 ratio, reduction in the mortality of the patients, and less number of patients were on ventilation, but there were no significant differences among the comparison and sarilumab group. Sarilumab did not have notable adverse events and can be considered a safe drug. Conclusion. Sarilumab is a safe drug with good clinical outcomes in patients with COVID-19 and, hence, could be used as an alternative regimen for the treatment. Further prospective studies exploring the relations with baseline biomarkers of inflammation commonly measured such as C-reactive protein and IL-6 would be necessary for a correlation with the treatment.http://dx.doi.org/10.1155/2021/8903435 |
| spellingShingle | Rajan Chamlagain Sangam Shah Basanta Sharma Paudel Roman Dhital Bipin Kandel Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review Interdisciplinary Perspectives on Infectious Diseases |
| title | Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review |
| title_full | Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review |
| title_fullStr | Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review |
| title_full_unstemmed | Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review |
| title_short | Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review |
| title_sort | efficacy and safety of sarilumab in covid 19 a systematic review |
| url | http://dx.doi.org/10.1155/2021/8903435 |
| work_keys_str_mv | AT rajanchamlagain efficacyandsafetyofsarilumabincovid19asystematicreview AT sangamshah efficacyandsafetyofsarilumabincovid19asystematicreview AT basantasharmapaudel efficacyandsafetyofsarilumabincovid19asystematicreview AT romandhital efficacyandsafetyofsarilumabincovid19asystematicreview AT bipinkandel efficacyandsafetyofsarilumabincovid19asystematicreview |